SCHEMBL164202

SCHEMBL164202

CC(C)(C)c1cc2nc(C(=O)c3ccc(F)cc3)nc(Cl)c2s1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.35
RAB9A P51151 4/20 0.35
ATM Q13315 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
CTDSP1 Q9GZU7 1/20 0.35
PRKCI P41743 3/20 0.34
MAPK14 Q16539 2/20 0.34
RXFP1 Q9HBX9 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
LMNA P02545 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
LTA4H P09960 1/20 0.33
PDPK1 O15530 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
LRRK2 Q5S007 1/20 0.33
ALOX5 P09917 1/20 0.33
KDM4E B2RXH2 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL164868 0.84 MEN1 (0.40) NPC1RAB9AATMNPSR1CTDSP1
SCHEMBL164536 0.77 NPC1 (0.49) NPC1RAB9AATMNPSR1CTDSP1
SCHEMBL166018 0.76 AURKA (0.56) AURKA
SCHEMBL164944 0.71 AURKA (0.41) NPC1RXFP1LMNAMAPTLTA4H
SCHEMBL164973 0.71 DHODH (0.41) NPC1RXFP1LTA4HMEN1KMT2A
SCHEMBL167507 0.69 ALDH1A1 (0.44) NPC1RAB9ASMN1; SMN2LMNATP53
SCHEMBL164030 0.69 KDM4E (0.50) NPC1RAB9AATMNPSR1CTDSP1
SCHEMBL159829 0.69 KDM4E (0.53) NPSR1SMN1; SMN2LMNATP53MAPT
SCHEMBL165012 0.68 ESR1 (0.41) KDM4EHTTAURKA
SCHEMBL4421206 0.68 PDPK1 (0.38) PRKCIPDPK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130317045-A1 THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2013-11-28 US disclosed
EP-2611812-A1 THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF Ambit Biosciences Corporation (US) 2013-07-10 EP disclosed
WO-2012030894-A1 THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF AMBIT BIOSCIENCES CORPORATION (US) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130317045-A1 THIENOPYRIDINE AND THIENOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF JAK2, JAK3, TYK2 NPC1 4484/4885RAB9A 3313/4885ATM 422/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.